Article

Small molecule drug discovery at the glucagon-like peptide-1 receptor.

Translational Science and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Experimental Diabetes Research (Impact Factor: 1.89). 01/2012; 2012:709893. DOI: 10.1155/2012/709893
Source: PubMed

ABSTRACT The therapeutic success of peptide glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes mellitus has inspired discovery efforts aimed at developing orally available small molecule GLP-1 receptor agonists. Although the GLP-1 receptor is a member of the structurally complex class B1 family of GPCRs, in recent years, a diverse array of orthosteric and allosteric nonpeptide ligands has been reported. These compounds include antagonists, agonists, and positive allosteric modulators with intrinsic efficacy. In this paper, a comprehensive review of currently disclosed small molecule GLP-1 receptor ligands is presented. In addition, examples of "ligand bias" and "probe dependency" for the GLP-1 receptor are discussed; these emerging concepts may influence further optimization of known molecules or persuade designs of expanded screening strategies to identify novel chemical starting points for GLP-1 receptor drug discovery.

1 Bookmark
 · 
191 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic β-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Like other class B G protein-coupled receptors (GPCRs), the GLP-1R contains an N-terminal extracellular ligand binding domain. N-terminal truncations on the peptide agonist generate antagonists capable of binding to the extracellular domain, but not capable of activating full length receptor. The main objective of this study was to use Hydrogen/deuterium exchange (HDX) to identify how the amide hydrogen bonding network of peptide ligands and the extracellular domain of GLP-1R (nGLP-1R) were altered by binding interactions and to then use this platform to validate direct binding events for putative GLP-1R small molecule ligands. The HDX studies presented here for two glucagon-like peptide-1 receptor (GLP-1R) peptide ligands indicates that the antagonist exendin-4[9-39] is significantly destabilized in the presence of nonionic detergents as compared to the agonist exendin-4. Furthermore, HDX can detect stabilization of exendin-4 and exendin-4[9-39] hydrogen bonding networks at the N-terminal helix [Val19 to Lys27] upon binding to the N-terminal extracellular domain of GLP-1R (nGLP-1R). In addition we show hydrogen bonding network stabilization on nGLP-1R in response to ligand binding, and validate direct binding events with the extracellular domain of the receptor for putative GLP-1R small molecule ligands.
    PLoS ONE 01/2014; 9(9):e105683. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lamiophlomis rotata is an orally available Tibetan herb prescribed for the management of pain, with shanzhiside methylester (SM) and 8-O-acetyl-SM as quality control ingredients. This study aimed to evaluate the antinociceptive properties of L. rotata, determine whether SM and 8-O-acetyl-SM are principle effective ingredients, and explore whether L. rotata produces antinociception through activation of spinal glucagon-like peptide-1 receptors (GLP-1Rs).
    Anesthesiology 10/2014; 121(4):835-851. · 5.16 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucagon-like peptide-1 receptor (GLP-1R) mediates the "incretin effect" and many other anti-diabetic actions of its cognate ligand, GLP-1. It belongs to the class B family of G protein-coupled receptors (GPCRs) and possesses an N-terminal putative signal peptide. It has been reported that this sequence is required for the synthesis of GLP-1R and is cleaved after receptor synthesis. In this study, we conducted an in-depth exploration towards the role of the putative signal peptide in GLP-1R synthesis. A mutant GLP-1R without this sequence was expressed in HEK293 cells and displayed normal functionality with respect to ligand binding and activation of adenylate cyclase. Thus, the putative signal peptide does not seem to be required for receptor synthesis. Immunoblotting analysis shows that the amount of GLP-1R synthesized in HEK293 cells is low when the putative signal peptide is absent. This indicates that the role of the sequence is to promote the expression of GLP-1R. Furthermore, epitopes tagged at the N-terminal of GLP-1R are detectable by immunofluorescence and immunoblotting in our experiments. In conclusion, the present study points to different roles of signal peptide in GLP-1R expression which broadens our understanding of the functionality of this putative signal peptide of GLP-1R, and possibly other Class B GPCRs.
    Bioscience Reports 10/2014; · 1.88 Impact Factor

Full-text (2 Sources)

Download
6 Downloads
Available from
Nov 11, 2014